Eli Lilly acquires psychedelic drug maker AtaiBeckley to expand mental health treatments

Pharmaceutical giant Eli Lilly has acquired AtaiBeckley, a company developing psychedelic drugs to treat mental health conditions. The deal marks a significant expansion of Big Pharma's embrace of a historically stigmatised class of medications. The acquisition signals that the market for psychedelic-assisted psychiatry is entering a new phase of commercialisation.